Navigation Links
Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
Date:1/13/2014

WALTHAM, Mass., Jan. 13, 2014 /PRNewswire/ -- EarlySense, the market leader in Proactive Patient Care Solutions, announced today the results of a small clinical trial conducted at Brigham and Women's Hospital in Boston that identifies complex respiratory patterns which were found to be correlated to patients' respiratory condition and have the potential to show when mechanical ventilation is no longer required.

"The study results show that unique, complex respiratory patterns have the potential to predict, on one hand, the patients' readiness to be separated from the ventilator, but, alternately, also the need for continued ventilatory support," said Dr. Gyorgy Frendl, MD, PhD, Director of Surgical Critical Care Research, Brigham and Women's Hospital, Assistant Professor of Anesthesia, Harvard Medical School, the Principal Investigator of the study. "For patients recently weaned from the ventilator, the appearance of these complex distress respiratory patterns indicated that they were likely to require further ventilator support:

  • Generalized disorganized respirations
  • Frequent [every 30-120 seconds] high amplitude gasping breaths
  • Periods of apnea >30 seconds

For ventilated patients, the above patterns indicated that the patient is not yet ready to be separated from the mechanical ventilator support.

"The ability to measure advanced respiratory patterns in a contact-free manner is a promising approach to improve care and keep patients safer," said Avner Halperin, CEO of EarlySense. We are honored that the EarlySense technology can determine respiratory patterns and provide clinicians with advanced tools to intervene effectively and, if required, early as evidenced in this study."

About Ea
'/>"/>

SOURCE EarlySense
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer
2. Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile
3. Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
4. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
5. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
6. Kaiser Permanente-Led Team to Become Integral Part of New National Clinical Research Network
7. Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
8. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
9. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
10. Croissance Clinical Research Collaborates with Acceliant for Clinical Trial Excellence
11. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/25/2015)... New Jersey (PRWEB) April 25, 2015 ... people aged twelve and above needed treatment for an ... according to the Substance Abuse and Mental Health Services ... September 2011). Beyond these alarming numbers are harrowing stories ... by substance abuse . David H. Kerr ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Carinsurancequotesinfo.com has released a new blog post that ... for flatbed trucks. , Flatbed trucks are ... They are mainly used for commercial purposes and thus ... explains that by comparing multiple offers, drivers can find ... vehicles. , It is now possible to compare free ...
(Date:4/25/2015)... By definition, a CIO’s responsibility is to support the ... their judgement and expertise to keep digital assets and environments ... article published in National Mortgage News on April 22nd, 2015 ... to their responsibilities by focusing too heavily on making sure ... it comes to company policy and industry best practices, and ...
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3
... The following is a,statement of SEIU spokesperson Andrew McDonald:, ... health and,vitality of any democratic organization., "For the last ... and full debate over the future of our union. For ... been the subject of,an even more vigorous debate -- in ...
... China, April 8, 2008 /Xinhua-PRNewswire-FirstCall/ --,Linkwell Corporation (Linkwell ... developer, manufacturer and distributor of healthcare related,disinfectants in ... year-end,financial results in a conference call on Wednesday, ... Company will release its 2007 year-end financial results ...
... rising on,everything from bread to education, and health care is ... a Medicaid patient in the home, the,urgent need for an ... to nurses and other home care advocates,visiting legislators today as ... cost of a nurse,s visit to a home care patient ...
... Mark your calendars for these,training and networking ... Detroit Chapter (IABC/Detroit)!, April 16 Luncheon Session: ... organization,s message impact its market,share? Find out when ... messaging has impacted today,s marketing landscape., Join ...
... School of Medicine and colleagues at Merck Serono Research ... receptor sites on some tumors in different places at ... combination therapy for certain types of cancer. , An ... called epidermal growth factor receptors (EGFR) sitting on their ...
... Newborns Vulnerable for Rare,Metabolic Conditions, WASHINGTON, April 8, ... the Bills to four consecutive Super,Bowls, will be on ... with,Members of Congress asking them to approve and fund ... also participate in a press event with Senators Christopher,Dodd ...
Cached Medicine News:Health News:Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Bayada Nurses Advocates for Increase in Medicaid Reimbursement Rate to Allow More Individuals to Receive Home Care and Hire More Skilled Staff 2Health News:IABC/Detroit Announces April Professional Development and Networking Events 2Health News:Double binding sites on tumor target may provide future combination therapy 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 3Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 4
Contains 5 mg of penicillin, 5 mg of streptomycin, and 10 mg of neomycin/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and neomycin sulfate in 0.85% saline....
Penicillin-Streptomycin liquid...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
... to buff-colored powder Activity: >=590g of gentamicin/mg (dry basis) ... Limit of Methanol: Specific Rotation (25C): +107 to ... 2 O): 3.5 to 5.5 Loss on drying: ... 25-50% C 2 + C 2a : 25-55% ...
Medicine Products: